Leginfo

Bill

Home - Bills - Bill - Authors - Dates - Keywords - Tags - Locations

Measure

AB 1152

Authors

Patterson

Subject

Controlled substances: human chorionic gonadotropin.

Relating To

relating to controlled substances.

Title

An act to amend Section 11056 of the Health and Safety Code, relating to controlled substances.

Last Action Dt

2025-10-01

State

Chaptered

Status

Chaptered

Active?

Vote Required

Majority

Appropriation

Fiscal Committee

Yes

Local Program

Substantive Changes

None

Urgency

Tax Levy

Leginfo Link

Bill

Actions

2025-10-01		Approved by the Governor.
2025-10-01		Chaptered by Secretary of State - Chapter 183, Statutes of 2025.
2025-09-24		Enrolled and presented to the Governor at 3 p.m.
2025-09-13		Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 74. Noes 0. Page 3505.).
2025-09-13		Joint Rules 61(a)(14) and 51(a)(4) suspended. (Ayes 59. Noes 20. Page 3413.)
2025-09-12		From committee: That the Senate amendments be concurred in. (Ayes 9. Noes 0.) (September 12).
2025-09-11		Joint Rule 62(a), file notice suspended. (Page 3319.)
2025-09-11		Re-referred to Com. on PUB. S. pursuant to Assembly Rule 77.2.
2025-09-10		In Assembly. Concurrence in Senate amendments pending.
2025-09-10		Read third time. Passed. Ordered to the Assembly. (Ayes 39. Noes 1. Page 2796.).
2025-09-03		Read second time. Ordered to third reading.
2025-09-02		Read third time and amended. Ordered to second reading.
2025-08-20		Read second time. Ordered to third reading.
2025-08-19		From committee: Be ordered to second reading pursuant to Senate Rule 28.8.
2025-07-15		From committee: Do pass and re-refer to Com. on APPR. with recommendation: To Consent Calendar. (Ayes 6. Noes 0.) (July 15). Re-referred to Com. on APPR.
2025-06-25		Re-referred to Com. on PUB. S.
2025-06-24		Withdrawn from committee.
2025-06-24		Re-referred to Com. on RLS.
2025-06-23		From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on L. GOV.
2025-05-21		Referred to Coms. on L. GOV. and HOUSING.
2025-05-08		Read third time. Passed. Ordered to the Senate. (Ayes 68. Noes 0. Page 1484.)
2025-05-08		In Senate. Read first time. To Com. on RLS. for assignment.
2025-05-05		Read second time. Ordered to third reading.
2025-05-01		From committee: Do pass. (Ayes 10. Noes 0.) (April 30).
2025-04-28		From committee: Do pass and re-refer to Com. on L. GOV. with recommendation: To Consent Calendar. (Ayes 11. Noes 0.) (April 24). Re-referred to Com. on L. GOV.
2025-04-24		(Pending re-refer to Com. on L. GOV.)
2025-04-24		Assembly Rule 56 suspended. (Page 1265.)
2025-04-01		Re-referred to Com. on H. & C.D.
2025-03-28		From committee chair, with author's amendments: Amend, and re-refer to Com. on H. & C.D. Read second time and amended.
2025-03-28		Referred to Coms. on H. & C.D. and L. GOV.
2025-02-21		From printer. May be heard in committee March 23.
2025-02-20		Read first time. To print.

Keywords

Tags

Versions

Chaptered		2025-10-01
Enrolled		2025-09-16
Amended Senate		2025-09-02
Amended Senate		2025-06-23
Amended Assembly		2025-03-28
Introduced		2025-02-20

Last Version Text

<?xml version="1.0" ?>
<ns0:MeasureDoc xmlns:html="http://www.w3.org/1999/xhtml" xmlns:ns0="http://lc.ca.gov/legalservices/schemas/caml.1#" xmlns:ns3="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" version="1.0" xsi:schemaLocation="http://lc.ca.gov/legalservices/schemas/caml.1# xca.1.xsd">
	


	<ns0:Description>
		<ns0:Id>20250AB__115294CHP</ns0:Id>
		<ns0:VersionNum>94</ns0:VersionNum>
		<ns0:History>
			<ns0:Action>
				<ns0:ActionText>INTRODUCED</ns0:ActionText>
				<ns0:ActionDate>2025-02-20</ns0:ActionDate>
			</ns0:Action>
			<ns0:Action>
				<ns0:ActionText>AMENDED_ASSEMBLY</ns0:ActionText>
				<ns0:ActionDate>2025-03-28</ns0:ActionDate>
			</ns0:Action>
			<ns0:Action>
				<ns0:ActionText>AMENDED_SENATE</ns0:ActionText>
				<ns0:ActionDate>2025-06-23</ns0:ActionDate>
			</ns0:Action>
			<ns0:Action>
				<ns0:ActionText>AMENDED_SENATE</ns0:ActionText>
				<ns0:ActionDate>2025-09-02</ns0:ActionDate>
			</ns0:Action>
			<ns0:Action>
				<ns0:ActionText>PASSED_ASSEMBLY</ns0:ActionText>
				<ns0:ActionDate>2025-09-13</ns0:ActionDate>
			</ns0:Action>
			<ns0:Action>
				<ns0:ActionText>PASSED_SENATE</ns0:ActionText>
				<ns0:ActionDate>2025-09-10</ns0:ActionDate>
			</ns0:Action>
			<ns0:Action>
				<ns0:ActionText>ENROLLED</ns0:ActionText>
				<ns0:ActionDate>2025-09-16</ns0:ActionDate>
			</ns0:Action>
			<ns0:Action>
				<ns0:ActionText>CHAPTERED</ns0:ActionText>
				<ns0:ActionDate>2025-10-01</ns0:ActionDate>
			</ns0:Action>
			<ns0:Action>
				<ns0:ActionText>APPROVED</ns0:ActionText>
				<ns0:ActionDate>2025-10-01</ns0:ActionDate>
			</ns0:Action>
			<ns0:Action>
				<ns0:ActionText>FILED</ns0:ActionText>
				<ns0:ActionDate>2025-10-01</ns0:ActionDate>
			</ns0:Action>
		</ns0:History>
		<ns0:LegislativeInfo>
			<ns0:SessionYear>2025</ns0:SessionYear>
			<ns0:SessionNum>0</ns0:SessionNum>
			<ns0:MeasureType>AB</ns0:MeasureType>
			<ns0:MeasureNum>1152</ns0:MeasureNum>
			<ns0:MeasureState>CHP</ns0:MeasureState>
			<ns0:ChapterYear>2025</ns0:ChapterYear>
			<ns0:ChapterType>CHP</ns0:ChapterType>
			<ns0:ChapterSessionNum>0</ns0:ChapterSessionNum>
			<ns0:ChapterNum>183</ns0:ChapterNum>
		</ns0:LegislativeInfo>
		<ns0:AuthorText authorType="LEAD_AUTHOR">Introduced by Assembly Member Patterson</ns0:AuthorText>
		<ns0:Authors>
			<ns0:Legislator>
				<ns0:Contribution>LEAD_AUTHOR</ns0:Contribution>
				<ns0:House>ASSEMBLY</ns0:House>
				<ns0:Name>Patterson</ns0:Name>
			</ns0:Legislator>
		</ns0:Authors>
		<ns0:Title> An act to amend Section 11056 of the Health and Safety Code, relating to controlled substances.</ns0:Title>
		<ns0:RelatingClause>controlled substances</ns0:RelatingClause>
		<ns0:GeneralSubject>
			<ns0:Subject>Controlled substances: human chorionic gonadotropin.</ns0:Subject>
		</ns0:GeneralSubject>
		<ns0:DigestText>
			<html:p>Existing law, the California Uniform Controlled Substances Act, categorizes controlled substances into 5 schedules and places the greatest restrictions on those substances contained in Schedule I. Under existing law, the substances in Schedule I are deemed to have a high potential for abuse and no accepted medical use while substances in Schedules II through V are substances that have an accepted medical use, but have the potential for abuse. Existing law generally restricts the prescription, furnishing, possession, sale, and use of controlled substances, and makes a violation of those laws a crime, except as specified. Existing law categorizes chorionic gonadotropin, including human chorionic gonadotropin (hCG), as a Schedule III controlled substance except when the hCG is possessed by, sold to, purchased by, transferred to, or administrated by, a licensed veterinarian or a licensed
		veterinarian’s designated agent, exclusively for veterinary use.</html:p>
			<html:p>This bill would remove hCG from the list of Schedule III controlled substances under the California Uniform Controlled Substances Act.</html:p>
		</ns0:DigestText>
		<ns0:DigestKey>
			<ns0:VoteRequired>MAJORITY</ns0:VoteRequired>
			<ns0:Appropriation>NO</ns0:Appropriation>
			<ns0:FiscalCommittee>YES</ns0:FiscalCommittee>
			<ns0:LocalProgram>NO</ns0:LocalProgram>
		</ns0:DigestKey>
		<ns0:MeasureIndicators>
			<ns0:ImmediateEffect>NO</ns0:ImmediateEffect>
			<ns0:ImmediateEffectFlags>
				<ns0:Urgency>NO</ns0:Urgency>
				<ns0:TaxLevy>NO</ns0:TaxLevy>
				<ns0:Election>NO</ns0:Election>
				<ns0:UsualCurrentExpenses>NO</ns0:UsualCurrentExpenses>
				<ns0:BudgetBill>NO</ns0:BudgetBill>
				<ns0:Prop25TrailerBill>NO</ns0:Prop25TrailerBill>
			</ns0:ImmediateEffectFlags>
		</ns0:MeasureIndicators>
	</ns0:Description>
	<ns0:Bill id="bill">
		<ns0:Preamble>The people of the State of California do enact as follows:</ns0:Preamble>
		<ns0:BillSection id="id_45299A66-B937-4CA5-989C-BD7DECE62DAC">
			<ns0:Num>SECTION 1.</ns0:Num>
			<ns0:ActionLine action="IS_AMENDED" ns3:href="urn:caml:codes:HSC:caml#xpointer(%2Fcaml%3ALawDoc%2Fcaml%3ACode%2Fcaml%3ALawHeading%5B%40type%3D'DIVISION'%20and%20caml%3ANum%3D'10.'%5D%2Fcaml%3ALawHeading%5B%40type%3D'CHAPTER'%20and%20caml%3ANum%3D'2.'%5D%2Fcaml%3ALawSection%5Bcaml%3ANum%3D'11056.'%5D)" ns3:label="fractionType: LAW_SECTION" ns3:type="locator">
				Section 11056 of the 
				<ns0:DocName>Health and Safety Code</ns0:DocName>
				 is amended to read:
			</ns0:ActionLine>
			<ns0:Fragment>
				<ns0:LawSection id="id_306FEE78-B380-49CF-AD37-D90BA6033280">
					<ns0:Num>11056.</ns0:Num>
					<ns0:LawSectionVersion id="id_13B0E987-9A53-4E8B-85FF-897C71D4DF18">
						<ns0:Content>
							<html:p>
								(a)
								<html:span class="EnSpace"/>
								The controlled substances listed in this section are included in Schedule III.
							</html:p>
							<html:p>
								(b)
								<html:span class="EnSpace"/>
								Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of those isomers whenever the existence of those salts, isomers, and salts of isomers is possible within the specific chemical designation:
							</html:p>
							<html:p>
								(1)
								<html:span class="EnSpace"/>
								Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or
				  preparations were listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other drug of the quantitative composition shown in that list for those drugs or that is the same except that it contains a lesser quantity of controlled substances.
							</html:p>
							<html:p>
								(2)
								<html:span class="EnSpace"/>
								Benzphetamine.
							</html:p>
							<html:p>
								(3)
								<html:span class="EnSpace"/>
								Chlorphentermine.
							</html:p>
							<html:p>
								(4)
								<html:span class="EnSpace"/>
								Clortermine.
							</html:p>
							<html:p>
								(5)
								<html:span class="EnSpace"/>
								Mazindol.
							</html:p>
							<html:p>
								(6)
								<html:span class="EnSpace"/>
								Phendimetrazine.
							</html:p>
							<html:p>
								(c)
								<html:span class="EnSpace"/>
								Depressants. Unless specifically excepted in Section 11059 or elsewhere, or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a
				  depressant effect on the central nervous system:
							</html:p>
							<html:p>
								(1)
								<html:span class="EnSpace"/>
								Any compound, mixture, or preparation containing any of the following:
							</html:p>
							<html:p>
								(A)
								<html:span class="EnSpace"/>
								Amobarbital.
							</html:p>
							<html:p>
								(B)
								<html:span class="EnSpace"/>
								Secobarbital.
							</html:p>
							<html:p>
								(C)
								<html:span class="EnSpace"/>
								Pentobarbital or any salt thereof and one or more other active medicinal ingredients that are not listed in any schedule.
							</html:p>
							<html:p>
								(2)
								<html:span class="EnSpace"/>
								Any suppository dosage form containing any of the following:
							</html:p>
							<html:p>
								(A)
								<html:span class="EnSpace"/>
								Amobarbital.
							</html:p>
							<html:p>
								(B)
								<html:span class="EnSpace"/>
								Secobarbital.
							</html:p>
							<html:p>
								(C)
								<html:span class="EnSpace"/>
								Pentobarbital or any salt of any of these drugs and approved by the federal Food and Drug Administration for
				  marketing only as a suppository.
							</html:p>
							<html:p>
								(3)
								<html:span class="EnSpace"/>
								Any substance that contains any quantity of a derivative of barbituric acid or any salt thereof.
							</html:p>
							<html:p>
								(4)
								<html:span class="EnSpace"/>
								Chlorhexadol.
							</html:p>
							<html:p>
								(5)
								<html:span class="EnSpace"/>
								Lysergic acid.
							</html:p>
							<html:p>
								(6)
								<html:span class="EnSpace"/>
								Lysergic acid amide.
							</html:p>
							<html:p>
								(7)
								<html:span class="EnSpace"/>
								Methyprylon.
							</html:p>
							<html:p>
								(8)
								<html:span class="EnSpace"/>
								Sulfondiethylmethane.
							</html:p>
							<html:p>
								(9)
								<html:span class="EnSpace"/>
								Sulfonethylmethane.
							</html:p>
							<html:p>
								(10)
								<html:span class="EnSpace"/>
								Sulfonmethane.
							</html:p>
							<html:p>
								(11)
								<html:span class="EnSpace"/>
								Gamma hydroxybutyric acid, and its salts, isomers, and salts of isomers, contained in a drug product for which an application has been approved under
				  Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 355).
							</html:p>
							<html:p>
								(d)
								<html:span class="EnSpace"/>
								Nalorphine.
							</html:p>
							<html:p>
								(e)
								<html:span class="EnSpace"/>
								Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
							</html:p>
							<html:p>
								(1)
								<html:span class="EnSpace"/>
								Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium.
							</html:p>
							<html:p>
								(2)
								<html:span class="EnSpace"/>
								Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
							</html:p>
							<html:p>
								(3)
								<html:span class="EnSpace"/>
								Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts.
							</html:p>
							<html:p>
								(4)
								<html:span class="EnSpace"/>
								Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
							</html:p>
							<html:p>
								(5)
								<html:span class="EnSpace"/>
								Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
							</html:p>
							<html:p>
								(6)
								<html:span class="EnSpace"/>
								Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic
				  amounts.
							</html:p>
							<html:p>
								(f)
								<html:span class="EnSpace"/>
								Anabolic steroids and chorionic gonadotropin, except for human chorionic
				  gonadotropin (hCG). Any material, compound, mixture, or preparation containing chorionic gonadotropin, except hCG, or an anabolic steroid (excluding anabolic steroid products listed in the “Table of Exempt Anabolic Steroid Products” (Section 1308.34 of Title 21 of the Code of Federal Regulations), as exempt from the federal Controlled Substances Act (Section 801 and following of Title 21 of the United States Code)), including, but not limited to, the following:
							</html:p>
							<html:p>
								(1)
								<html:span class="EnSpace"/>
								Androisoxazole.
							</html:p>
							<html:p>
								(2)
								<html:span class="EnSpace"/>
								Androstenediol.
							</html:p>
							<html:p>
								(3)
								<html:span class="EnSpace"/>
								Bolandiol.
							</html:p>
							<html:p>
								(4)
								<html:span class="EnSpace"/>
								Bolasterone.
							</html:p>
							<html:p>
								(5)
								<html:span class="EnSpace"/>
								Boldenone.
							</html:p>
							<html:p>
								(6)
								<html:span class="EnSpace"/>
								Chloromethandienone.
							</html:p>
							<html:p>
								(7)
								<html:span class="EnSpace"/>
								Clostebol.
							</html:p>
							<html:p>
								(8)
								<html:span class="EnSpace"/>
								Dihydromesterone.
							</html:p>
							<html:p>
								(9)
								<html:span class="EnSpace"/>
								Ethylestrenol.
							</html:p>
							<html:p>
								(10)
								<html:span class="EnSpace"/>
								Fluoxymesterone.
							</html:p>
							<html:p>
								(11)
								<html:span class="EnSpace"/>
								Formyldienolone.
							</html:p>
							<html:p>
								(12)
								<html:span class="EnSpace"/>
								4-Hydroxy-19-nortestosterone.
							</html:p>
							<html:p>
								(13)
								<html:span class="EnSpace"/>
								Mesterolone.
							</html:p>
							<html:p>
								(14)
								<html:span class="EnSpace"/>
								Methandriol.
							</html:p>
							<html:p>
								(15)
								<html:span class="EnSpace"/>
								Methandrostenolone.
							</html:p>
							<html:p>
								(16)
								<html:span class="EnSpace"/>
								Methenolone.
							</html:p>
							<html:p>
								(17)
								<html:span class="EnSpace"/>
								17-Methyltestosterone.
							</html:p>
							<html:p>
								(18)
								<html:span class="EnSpace"/>
								Methyltrienolone.
							</html:p>
							<html:p>
								(19)
								<html:span class="EnSpace"/>
								Nandrolone.
							</html:p>
							<html:p>
								(20)
								<html:span class="EnSpace"/>
								Norbolethone.
							</html:p>
							<html:p>
								(21)
								<html:span class="EnSpace"/>
								Norethandrolone.
							</html:p>
							<html:p>
								(22)
								<html:span class="EnSpace"/>
								Normethandrolone.
							</html:p>
							<html:p>
								(23)
								<html:span class="EnSpace"/>
								Oxandrolone.
							</html:p>
							<html:p>
								(24)
								<html:span class="EnSpace"/>
								Oxymesterone.
							</html:p>
							<html:p>
								(25)
								<html:span class="EnSpace"/>
								Oxymetholone.
							</html:p>
							<html:p>
								(26)
								<html:span class="EnSpace"/>
								Quinbolone.
							</html:p>
							<html:p>
								(27)
								<html:span class="EnSpace"/>
								Stanolone.
							</html:p>
							<html:p>
								(28)
								<html:span class="EnSpace"/>
								Stanozolol.
							</html:p>
							<html:p>
								(29)
								<html:span class="EnSpace"/>
								Stenbolone.
							</html:p>
							<html:p>
								(30)
								<html:span class="EnSpace"/>
								Testosterone.
							</html:p>
							<html:p>
								(31)
								<html:span class="EnSpace"/>
								Trenbolone.
							</html:p>
							<html:p>
								(g)
								<html:span class="EnSpace"/>
								Ketamine. Any material, compound, mixture, or preparation containing ketamine.
							</html:p>
							<html:p>
								(h)
								<html:span class="EnSpace"/>
								Hallucinogenic substances. Any of the following hallucinogenic substances: dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the federal Food and Drug Administration.
							</html:p>
						</ns0:Content>
					</ns0:LawSectionVersion>
				</ns0:LawSection>
			</ns0:Fragment>
		</ns0:BillSection>
	</ns0:Bill>
</ns0:MeasureDoc>

Last Version Text Digest

Existing law, the California Uniform Controlled Substances Act, categorizes controlled substances into 5 schedules and places the greatest restrictions on those substances contained in Schedule I. Under existing law, the substances in Schedule I are deemed to have a high potential for abuse and no accepted medical use while substances in Schedules II through V are substances that have an accepted medical use, but have the potential for abuse. Existing law generally restricts the prescription, furnishing, possession, sale, and use of controlled substances, and makes a violation of those laws a crime, except as specified. Existing law categorizes chorionic gonadotropin, including human chorionic gonadotropin (hCG), as a Schedule III controlled substance except when the hCG is possessed by, sold to, purchased by, transferred to, or administrated by, a licensed veterinarian or a licensed veterinarian’s designated agent, exclusively for veterinary use. This bill would remove hCG from the list of Schedule III controlled substances under the California Uniform Controlled Substances Act.